- BGI Successful Participation in 15th China-ASEAN Expo to Further Promote the China-ASEAN Cooperation Under Belt and Road
- A Delegation from Silicon Valley Bank Visits CNGB and BGI Headquarters
- Delegation form STI Policy Research and Method in Belt and Road Countries Workshop and CISTRAT Visits CNGB
- BGI Attends the 2018 Beijing Summit of the Forum on China-Africa Cooperation to Show its Support for Cooperation
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: email@example.com
Shenzhen, China– Recently, BGI announced that Dr. Leroy Hood, a world renowned scientist and genomics pioneer, has joined the company’s Scientific Advisory Board.
Dr. Hood, a pioneer in the systems approach to biology and medicine, is president and co-founder of the Institute for Systems Biology and senior vice president and chief scientific officer of Providence St. Joseph Health, based in Seattle.
Dr. Hood was involved in the development of five instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine.
In addition to his ground-breaking research, Dr. Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine.
As the member of BGI’s Scientific Advisory Board, Dr. Hood will devote efforts to provide professional advice based on his rich experience and insights in the field.
"BGI has enormous ambitions with a broad scope and expertise in many kinds of genomes, from humans to animals, plants and microbes,” Dr. Hood said in a statement. “I think they are absolutely right to push sequencing technology to its limit. I am interested in learning about BGI’s approaches to human health, and in finding our common interests to advance medicine.”
Dr. Yiwu He, BGI’s Global Head of Research & Development, said, “Dr. Hood is a world class leader in genomic sequencing and precision medicine. His vision and wisdom will add huge value to BGI’s efforts to solve healthcare problems with cutting-edge technologies and innovative solutions.”